Summary: Two existing medications have been repurposed to treat sleep apnea.
Researchers report the medications reduce symptoms of sleep apnea by 30%.
Source: The Physiological Society
New research published in The Journal of Physiology shows that researchers
have successfully repurposed two existing medications to reduce the severity of
sleep apnea in people by at least 30 percent.
Affecting around 1.5 million adults in the UK, sleep apnea is a condition
where the upper airway from the back of the nose to the throat closes
repetitively during sleep, restricting oxygen intake and causing people to wake
as often as 100 times or more per hour.
Those with untreated sleep apnea are more likely to develop cardiovascular
disease, dementia and depression, and are two to four times more likely to
crash a car than the general population.
Despite almost thirty years of research, there are no approved drug
therapies to treat the condition.
Professor Danny Eckert, Principal Research Scientist at NeuRA and Professor
and Director of Adelaide Institute for Sleep Health at Flinders University, has
brought scientists one step closer by repurposing two existing medications to
test their efficacy in people in sleep apnea.
Previous research showed two classes of medication, reboxetine and
butylbromide, were able to keep muscles active during sleep in people without
sleep apnoea, and assist their ability to breathe.
By repurposing the medications, researchers used a multitude of recording
instruments to measure whether reboxetine and butylbromide could successfully
target the main causes of sleep apnoea.
This included balancing the electrical activity of muscles around the
airway, preventing the throat from collapsing while people were sleeping, and
improving the regulation of carbon dioxide and breathing during sleep.
Results from the study showed these medications did in fact increase the
muscle activity around participants’ airways, with the drugs reducing the
severity of participants’ sleep apnoea by up to one third.
Almost everyone we studied had some improvement in sleep apnoea. People’s
oxygen intake improved, their number of breathing stoppages was a third or
more.
These new findings allow researchers to further refine these types of
medications so that they have even greater benefit than what has currently been
found.
Commenting on the study, Professor Eckert said:
“We were thrilled because the current treatment options for people with
sleep apnoea are limited and can be a painful journey for many,” he said. Next,
we will look at the effects of these and similar medications over the longer
term. We will assess whether we can harness the benefits of one drug without
needing to use them both.”
Despite
almost thirty years of research, there are no approved drug therapies to treat
the condition. Image is in the public domain
“Equally,
we will test whether these treatments can be combined with other existing
medications to see if we can improve their efficacy even more,” he continued.
Until
now, the main therapy for sleep apnoea involves wearing a mask to bed, or
Continuous Positive Airway Pressure Therapy (CPAP), which benefits millions.
However, many people find it uncomfortable and half the people that try it find
it hard to tolerate.
Plus, the
efficacy of second line therapies, such as mouthguards fitted by dentists, can
be unpredictable and expensive.
Funding:
This study was funded by the National Health and Medical Research Council of
Australia.
Source:
The Physiological SocietyContact: Julia Turan – The Physiological SocietyImage:
The image is in the public domain
Original
Research: Closed access.“The noradrenergic agent reboxetine plus antimuscarinic
hyoscine butylbromide reduces sleep apnoea severity: A double-blind,
placebo-controlled, randomised crossover trial” by Danny Eckert et al. Journal
of Physiology
Abstract
The
noradrenergic agent reboxetine plus antimuscarinic hyoscine butylbromide
reduces sleep apnoea severity: A double-blind, placebo-controlled, randomised
crossover trial
The
noradrenergic agent reboxetine combined with the anti-muscarinic hyoscine
butylbromide has recently been shown to improve upper airway function during
sleep in healthy individuals. However, the effects of this drug combination on
obstructive sleep apnoea (OSA) severity are unknown.
Accordingly,
this study aimed to determine if reboxetine plus hyoscine butylbromide reduces
OSA severity. Secondary aims were to investigate the effects on key
upper-airway physiology and endotypic traits. 12 people with OSA aged 52±13
years, BMI = 30±5 kg/m2 completed a double-blind, randomised,
placebo-controlled, cross-over trial (ACTRN12617001326381). Two in-laboratory
sleep studies with nasal mask, pneumotachograph, epiglottic pressure sensor and
bipolar fine-wire electrodes into genioglossus and tensor palatini muscles were
performed separated by approximately 1-week.
Each
participant received either reboxetine (4mg) plus hyoscine butylbromide (20mg),
or placebo immediately prior to sleep. Polysomnography, upper-airway physiology
and endotypic estimates of OSA were compared between conditions. Reboxetine
plus hyoscine butylbromide reduced the apnoea/hypopnoea index by (mean±SD)
17±17 events/h from 51±30 to 33±22 events/h (p = 0.005) and nadir oxygen
saturation increased by 6±5% from 82±5 to 88±2% (p = 0.002).
The drug
combination increased tonic genioglossus muscle responsiveness during non-REM
sleep (median [25th, 75th centiles]: -0.007[-0.0004, -0.07] vs.
-0.12[-0.02, -0.40] %maxEMG/cmH2O, p = 0.02), lowered loop gain (0.43±0.06 vs.
0.39±0.07, p = 0.01), and improved airway collapsibility (90[69, 95] vs. 93[88,
96] %eupnea, p = 0.02), without changing the arousal threshold (p = 0.39).
These
findings highlight the important role that noradrenergic and muscarinic
processes have on upper airway function during sleep and the potential for
pharmacotherapy to target these mechanisms to treat OSA.
Contact :
TriMedicare
Sleep Care Unit
1st Floor, 68/113A Jessore Road, Amarpally, Dum Dum, Kolkata – 700074
Email : trimedicare@aol.com
Call : (+91) 7003945473
(+91) 8777052658
(+91) 9883235935
0 Comments